Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.

ABSTRACT: Prostate cancer is the most common malignancy in men in the United States. While androgen deprivation therapy results in tumor responses initially, there is relapse and progression to metastatic castration-resistant prostate cancer. Currently, all prostate cancer patients receive essentially the same treatment, and there is a need for clinically applicable technologies to provide predictive biomarkers toward personalized therapies. Genomic analyses of tumors are used for clinical applications, but with a paucity of obvious driver mutations in metastatic castration-resistant prostate cancer, other applications, such as phosphoproteomics, may complement this approach. Immunohistochemistry and reverse phase protein arrays are limited by the availability of reliable antibodies and evaluates a

SUBMITTER: Ramroop JR 

PROVIDER: S-EPMC5820335 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature